Stifel Keeps Inovio Pharma (INO) at 'Buy' Following Q1 Report; Cash Position Expected to Remain Firm on New Grants

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. GOOGL
6. APGE
7. USO
8. IBM
9. HOOD
10. DFTX

Go back to Stifel Keeps Inovio Pharma (INO) at 'Buy' Following Q1 Report; Cash Position Expected to Remain Firm on New Grants

Inovio Pharma (INO) Tops Q1 EPS by 3c; Provides Corp. Update

May 9, 2016 7:52 AM EDT

Inovio Pharma (NASDAQ: INO) reported Q1 EPS of ($0.11), $0.03 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $8.1 million versus the consensus estimate of $4.75 million.

Corporate Update

Clinical Development

Subsequent to the quarter, Inovio held constructive meetings with both FDA (end of phase II) and European Medicines Agency (EMA) providing an affirmative path forward toward an indication for VGX-3100 to treat HPV-16/18-related... More